{
  "items": "32",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Psyence Biomedical stock rises after ethics approval for psilocybin trial",
      "url": "https://www.investing.com/news/stock-market-news/psyence-biomedical-stock-rises-after-ethics-approval-for-psilocybin-trial-93CH-4417451",
      "time_published": "20251220T110933",
      "authors": [
        "Investing.com"
      ],
      "summary": "Psyence Biomedical Ltd (NASDAQ:PBM) saw its stock increase after its psilocybin formulation, NPX5, received ethics committee approval for its Phase IIb clinical trial in Australia. This approval allows Psyence to move forward with its trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients, marking a crucial step towards vertical integration in the psychedelics sector. The company plans to accelerate patient recruitment by activating additional clinical sites for the study which is expected to deliver top-line results in 2026.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXMPECBE0OL_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934928"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.730790"
        }
      ],
      "overall_sentiment_score": 0.619609,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.604561",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical\u2019s psilocybin approved for Phase IIb trial use By Investing.com",
      "url": "https://ng.investing.com/news/company-news/psyence-biomedicals-psilocybin-approved-for-phase-iib-trial-use-93CH-2262487",
      "time_published": "20251220T110834",
      "authors": [
        "Investing.com"
      ],
      "summary": "Psyence Biomedical Ltd. announced that its PsyLabs\u2122 psilocybin product has received approval for use in an ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The trial will enroll approximately 87 participants across Australian sites and is expected to deliver top-line results in 2026. This approval marks a pivotal advancement for the company's clinical program and vertical integration strategy.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com Nigeria",
      "category_within_source": "General",
      "source_domain": "Investing.com Nigeria",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904200"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.742845"
        }
      ],
      "overall_sentiment_score": 0.512667,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.535744",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "{Company Name} Stock Soars on Exciting Developments",
      "url": "https://stockstotrade.com/news/psyence-biomedical-ltd-pbm-news-2025_12_19/",
      "time_published": "20251219T200858",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Psyence Biomedical Ltd. stock (NASDAQ: PBM) is experiencing a downturn despite promising advancements and strategic moves by the company. Factors such as a solid price-to-book ratio, strong return on equity, and healthy cash reserves indicate financial resilience. The company aims for sustained growth by leveraging market position and adapting to emerging trends, requiring traders to apply a disciplined, unemotional approach according to trainer Tim Bohen.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/12/dynamic-stock-market-trends-27.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.929631"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.842889"
        },
        {
          "topic": "finance",
          "relevance_score": "0.708807"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.637543"
        }
      ],
      "overall_sentiment_score": 0.040818,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "0.348673",
          "ticker_sentiment_score": "0.036001",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Psyence BioMed Announces Approval For Use Of Psylabs\u2019 Psilocybin Product In Phase IIb Clinical Trial",
      "url": "https://www.tradingview.com/news/reuters.com,2025:newsml_TUA9TGDQL:0-psyence-biomed-announces-approval-for-use-of-psylabs-psilocybin-product-in-phase-iib-clinical-trial/",
      "time_published": "20251219T120858",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed has announced the approval for the use of Psylabs\u2019 psilocybin product in a Phase IIb clinical trial. The company, Psyence Biomedical Ltd (PBM), stated that the study remains on track to deliver top-line results in 2026. This development marks a significant step forward in the clinical research of psilocybin.",
      "banner_image": "NULL",
      "source": "TradingView \u2014 Track All Markets",
      "category_within_source": "General",
      "source_domain": "TradingView \u2014 Track All Markets",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921979"
        }
      ],
      "overall_sentiment_score": 0.413628,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401552",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psychedelic therapy trial for patients with cancer moves forward in Australia",
      "url": "https://www.stocktitan.net/news/PBM/psyence-bio-med-announces-approval-for-use-of-psy-labs-psilocybin-iliqi8w38985.html",
      "time_published": "20251219T120858",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed announced that the Bellberry Human Research Ethics Committee approved the use of PsyLabs\u2019 psilocybin product (NPX5) in its Phase IIb clinical trial for adjustment disorder in cancer patients. This approval strengthens the company's vertically integrated model, ensuring supply-chain control and manufacturing excellence. The trial will enroll approximately 87 participants, testing two therapeutic doses against a low-dose comparator, with top-line results expected in 2026.",
      "banner_image": "https://ml.globenewswire.com/media/MmFhNTJjMzItZTE2Yi00OTMyLTg3MTEtM2Q0NzIxNzgwNmZlLTEyOTc0NjctMjAyNS0xMi0xOS1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.268739,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.285925",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical\u2019s psilocybin approved for Phase IIb trial use By Investing.com",
      "url": "https://au.investing.com/news/company-news/psyence-biomedicals-psilocybin-approved-for-phase-iib-trial-use-93CH-4179264",
      "time_published": "20251219T110858",
      "authors": [
        "Investing.com"
      ],
      "summary": "Psyence Biomedical Ltd. announced that its PsyLabs\u2122 psilocybin product has been approved by the Bellberry Human Research Ethics Committee for a Phase IIb clinical trial. This trial will evaluate psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients across multiple Australian sites, with top-line results expected in 2026. This approval marks a significant step in the company's clinical program and vertical integration strategy.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.705422"
        }
      ],
      "overall_sentiment_score": 0.400839,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.437365",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Announces Approval for Use of PsyLabs\u2019 Psilocybin Product in Phase IIb Clinical Trial",
      "url": "https://www.globenewswire.com/news-release/2025/12/19/3208411/0/en/Psyence-BioMed-Announces-Approval-for-Use-of-PsyLabs-Psilocybin-Product-in-Phase-IIb-Clinical-Trial.html",
      "time_published": "20251219T110858",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed announced that the Bellberry Human Research Ethics Committee has approved the use of PsyLabs\u2019 psilocybin product (NPX5) in its Phase IIb clinical trial for Adjustment Disorder in cancer patients, bolstering its vertically integrated psychedelic enterprise. This approval allows PsyLabs' GMP compliant, nature-derived psilocybin to be used in the double-blind, randomized trial, reinforcing Psyence BioMed's control over its supply chain and manufacturing. With approximately $9.5 million in cash, the Company is positioned to accelerate patient recruitment and aims to deliver top-line results in 2026.",
      "banner_image": "https://ml.globenewswire.com/media/MmFhNTJjMzItZTE2Yi00OTMyLTg3MTEtM2Q0NzIxNzgwNmZlLTEyOTc0NjctMjAyNS0xMi0xOS1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.924716"
        },
        {
          "topic": "finance",
          "relevance_score": "0.716059"
        }
      ],
      "overall_sentiment_score": 0.40496,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.425014",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science",
      "url": "https://www.sahmcapital.com/news/content/psyence-biomed-ceo-letter-highlights-clinical-progress-ethical-sourcing-of-ibogaine-strong-cash-position-and-expanding-leadership-in-longevity-science-2025-12-09",
      "time_published": "20251213T110858",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed's CEO, Jody Aufrichtig, released a year-end letter detailing the company's achievements in 2025 and its strategic vision for 2026. The letter highlights clinical progress in its Phase IIb trial for Adjustment Disorder, strengthened supply chains including ethical sourcing of ibogaine, and a strong cash position of over USD $9 million. The company also emphasizes its unique position as the only publicly listed psychedelics company investing significantly in longevity science.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910214"
        }
      ],
      "overall_sentiment_score": 0.498645,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.479152",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Advances Phase IIb Clinical Trial and Expands Board",
      "url": "https://www.msn.com/en-us/money/savingandinvesting/psyence-biomed-advances-phase-iib-clinical-trial-and-expands-board/ar-AA1QbzuG?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
      "time_published": "20251212T081015",
      "authors": [],
      "summary": "Psyence BioMed is advancing its Phase IIb clinical trial for glioblastoma treatment and has expanded its Board of Advisors. The trial is now open for enrollment in the UK, with the drug candidate showing promise in previous studies. These developments underscore the company's commitment to tackling rare and aggressive cancers and strengthening its leadership.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943743"
        }
      ],
      "overall_sentiment_score": 0.530973,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.522555",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed (PBM) Stock: Drives Forward with Phase IIb Trial and Unique Longevity Science Position",
      "url": "https://parameter.io/psyence-biomed-pbm-stock-drives-forward-with-phase-iib-trial-and-unique-longevity-science-position/",
      "time_published": "20251209T230945",
      "authors": [
        "Yasmin Werner"
      ],
      "summary": "Psyence BioMed (PBM) is advancing its Phase IIb clinical trial for psilocybin-assisted psychotherapy and uniquely positioning itself in longevity science despite recent stock volatility. The company boasts strong cash reserves of over $9 million and is debt-free, ready to fund future clinical trials and expand manufacturing. Psyence BioMed also secured GMP-compliant supply for psilocybin and ibogaine, enhancing its leadership in psychedelic compound production.",
      "banner_image": "https://parameter.io/wp-content/uploads/2025/11/hori-anim.gif",
      "source": "Parameter",
      "category_within_source": "General",
      "source_domain": "Parameter",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.918324"
        }
      ],
      "overall_sentiment_score": -0.204181,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.188258",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical Ltd. (PBM) Stock: Drops, But Company Pushes Forward with Groundbreaking Psychedelic Therapies",
      "url": "https://parameter.io/psyence-biomedical-ltd-pbm-stock-drops-but-company-pushes-forward-with-groundbreaking-psychedelic-therapies/",
      "time_published": "20251209T210945",
      "authors": [
        "Yasmin Werner"
      ],
      "summary": "Psyence Biomedical (PBM) experienced a 7.1% stock price decline, currently at $1.5700, yet the company continues to push forward with its innovative psychedelic therapies. Despite market fluctuations, PBM has made significant advancements in its Phase IIb clinical trial for psilocybin-assisted psychotherapy and strengthened its supply chain for GMP-compliant psilocybin and ibogaine. The company is also uniquely investing in the intersection of psychedelics and longevity science, aiming to explore therapies for extending healthspan.",
      "banner_image": "https://parameter.io/wp-content/uploads/2025/08/finance-4.jpg",
      "source": "Parameter",
      "category_within_source": "General",
      "source_domain": "Parameter",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.933801"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.835292"
        }
      ],
      "overall_sentiment_score": -0.123474,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.142284",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Rapid Surge: Psyence Biomedical\u2019s Unexpected Stock Movement",
      "url": "https://stockstotrade.com/news/psyence-biomedical-ltd-pbm-news-2025_12_09/",
      "time_published": "20251209T140945",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Psyence Biomedical Ltd. (PBM) experienced unexpected upward stock momentum driven by a new AI-driven drug development initiative and promising neuroscience research, despite an overall -8.28% downtrend on December 9, 2025. Financial analysis reveals resiliency with substantial cash reserves, high return on equity, and an undervalued price-to-book ratio. Analysts are revising projections, suggesting potential growth as the company navigates transformative research and collaborative platforms.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/12/ai-driven-stock-market-innovation-1.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.919570"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.922220"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.937084"
        },
        {
          "topic": "technology",
          "relevance_score": "0.641014"
        },
        {
          "topic": "finance",
          "relevance_score": "0.628413"
        }
      ],
      "overall_sentiment_score": 0.041648,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "0.323630",
          "ticker_sentiment_score": "0.020864",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science",
      "url": "https://www.globenewswire.com/news-release/2025/12/09/3202195/0/en/Psyence-BioMed-CEO-Letter-Highlights-Clinical-Progress-Ethical-Sourcing-of-Ibogaine-Strong-Cash-Position-and-Expanding-Leadership-in-Longevity-Science.html",
      "time_published": "20251209T121004",
      "authors": [],
      "summary": "Psyence BioMed's CEO, Jody Aufrichtig, issued a year-end letter detailing the company's 2025 achievements, including dosing patients in a Phase IIb clinical trial, securing a sustainable ibogaine supply chain through an investment in PsyLabs, and ending the year debt-free with over $9 million in cash. The company is actively investing in longevity science, focusing on the emotional and neurobiological dimensions of aging, and plans to accelerate trial enrollment and expand its manufacturing footprint in 2026.",
      "banner_image": "https://ml.globenewswire.com/media/YTIyMDdkYjItMzZmNi00ZmU4LWJhMzAtZjY0MmM5NTE2YzhhLTEyOTc0NjctMjAyNS0xMi0wOS1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930427"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.848402"
        }
      ],
      "overall_sentiment_score": 0.468872,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.475665",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed (Nasdaq: PBM) advances Phase IIb trial, ibogaine supply leadership",
      "url": "https://www.stocktitan.net/news/PBM/psyence-bio-med-ceo-letter-highlights-clinical-progress-ethical-z54lcfcq5qtf.html",
      "time_published": "20251209T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed (Nasdaq: PBM) CEO Jody Aufrichtig outlined 2025 achievements and 2026 priorities, including progress in a Phase IIb trial for psilocybin-assisted psychotherapy, a multi-million-dollar investment in PsyLabs for GMP psilocybin and ibogaine supply, and a strong cash position of over USD $9 million. The company is also expanding into longevity science and monitoring regulatory developments in Australia. Despite positive operational updates, the stock experienced a negative market reaction following the news, which fits a recent pattern.",
      "banner_image": "https://ml.globenewswire.com/media/YTIyMDdkYjItMzZmNi00ZmU4LWJhMzAtZjY0MmM5NTE2YzhhLTEyOTc0NjctMjAyNS0xMi0wOS1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936203"
        }
      ],
      "overall_sentiment_score": -0.224329,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.189392",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science",
      "url": "https://finance.yahoo.com/news/psyence-biomed-ceo-letter-highlights-120000551.html",
      "time_published": "20251209T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence Biomedical Ltd. (Nasdaq: PBM) CEO, Jody Aufrichtig, released a year-end letter summarizing achievements and outlining the strategic vision for 2026. The company highlights clinical progress in its Phase IIb trial, strengthened manufacturing and supply chains for nature-derived psilocybin and ibogaine, and its expanding leadership in longevity science. Psyence BioMed concluded 2025 debt-free with over USD $9 million in cash reserves, positioning itself for continued growth and expansion in 2026.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.945432"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.840332"
        }
      ],
      "overall_sentiment_score": 0.575138,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.572901",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed leads longevity research on psilocybin",
      "url": "https://longevity.technology/news/psyence-biomed-leads-longevity-research-on-psilocybin/",
      "time_published": "20251127T131015",
      "authors": [
        "Kyle Umipig"
      ],
      "summary": "Psyence BioMed, a publicly listed company, has initiated a pioneering research program to investigate psilocybin's potential effects on biological aging and healthspan markers. This collaboration with South African researchers positions Psyence BioMed at the forefront of exploring psychedelics for longevity, alongside its existing clinical trials for mental wellness. The study aims to determine if psilocybin can influence cellular resilience, inflammation, and mitochondrial function, offering new avenues for extending healthy human life.",
      "banner_image": null,
      "source": "Longevity.Technology",
      "category_within_source": "General",
      "source_domain": "Longevity.Technology",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948802"
        }
      ],
      "overall_sentiment_score": 0.444122,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.442495",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program",
      "url": "https://stocktwits.com/news-articles/business/others/psyence-bio-med-announces-groundbreaking-psilocybin-longevity-research-program/cL52kYzREg2",
      "time_published": "20251125T101500",
      "authors": [
        "Stocktwits PR Desk"
      ],
      "summary": "Psyence BioMed announced the launch of a new psilocybin longevity research initiative in collaboration with South African researchers, positioning itself as the first publicly listed company to investigate psilocybin\u2019s potential impact on biological aging markers. This program aims to evaluate psilocybin's influence on cellular stress, inflammation, mitochondrial function, and behavioral indicators associated with healthspan and lifespan. The research complements Psyence BioMed\u2019s existing clinical development programs, furthering its mission to explore the full therapeutic potential of psilocybin and ibogaine.",
      "banner_image": "https://news.stocktwits-cdn.com/Screenshot_2025_11_20_at_7_06_40_AM_png_c070083b64.webp",
      "source": "Stocktwits",
      "category_within_source": "General",
      "source_domain": "Stocktwits",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.943773"
        }
      ],
      "overall_sentiment_score": 0.472136,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "0.956197",
          "ticker_sentiment_score": "0.469351",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed (Nasdaq: PBM) Starts First Psilocybin Longevity Biomarker Study",
      "url": "https://www.stocktitan.net/news/PBM/psyence-bio-med-announces-groundbreaking-psilocybin-longevity-ekvvxflvzwbn.html",
      "time_published": "20251124T043322",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed (Nasdaq: PBM) has initiated a psilocybin longevity research program, becoming the first publicly listed company to investigate psilocybin's impact on biological aging markers. The study, led by Dr. Tanya Calvey in collaboration with South African researchers, will examine biomarkers related to cellular stress, inflammation, and mitochondrial function, with full acceleration expected after ethics approval. This initiative complements PBM's existing clinical programs and aims to explore psilocybin's potential in redefining human longevity.",
      "banner_image": "https://ml.globenewswire.com/media/NThkYjRiZTktYThmMy00ODkyLWJiM2EtOTgyNTVmMGIyODUwLTEyOTc0NjctMjAyNS0xMS0yNS1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.303774,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.301571",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Is PBM\u2019s Market Boost a Fleeting Mirage?",
      "url": "https://stockstotrade.com/news/psyence-biomedical-ltd-pbm-news-2025_11_20/",
      "time_published": "20251120T150400",
      "authors": [
        "Tim Bohen",
        "Ben Sturgill",
        "Ellis Hobbs"
      ],
      "summary": "Psyence Biomedical Ltd. (PBM) stock has seen significant volatility, initially experiencing a boost followed by a 22.57% downturn, raising questions about the sustainability of its market performance. Despite a strong cash position and high return on equity, negative return on assets indicates areas for improvement. The article explores the speculative nature of its market movements, driven by promising research and potential regulatory advancements in biotech.",
      "banner_image": "https://content.stockstotrade.com/wp-content/uploads/2025/11/biotech-stock-market-volatility-4.png",
      "source": "StocksToTrade",
      "category_within_source": "General",
      "source_domain": "StocksToTrade",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.900228"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.828131"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.726102"
        }
      ],
      "overall_sentiment_score": -0.380543,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.413202",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets",
      "url": "https://www.globenewswire.com/news-release/2025/11/20/3191764/0/en/Psyence-BioMed-Reaches-Major-Breakthrough-in-Pharmaceutical-Grade-Ibogaine-Supply-for-Worldwide-Clinical-and-Therapeutic-Markets.html",
      "time_published": "20251120T070000",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed has secured a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, a significant step for its ibogaine clinical development for substance use disorders. This collaboration ensures a long-term supply of GMP-compliant active pharmaceutical ingredients, including both purified ibogaine HCL and Total Alkaloid Extracts for research and treatment. The company emphasizes ethical sourcing with fair benefit-sharing, reinforcing its commitment to scientific rigor and responsible innovation in the emerging ibogaine sector.",
      "banner_image": "https://ml.globenewswire.com/media/ZmQ5NThjNTUtMDJlNi00MTFhLTg0M2ItODkwMzhhZDBlYTFiLTEyOTc0NjctMjAyNS0xMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.459122,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.483119",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed (Nasdaq: PBM) secures 50kg ibogaine supply for global clinical use",
      "url": "https://www.stocktitan.net/news/PBM/psyence-bio-med-reaches-major-breakthrough-in-pharmaceutical-grade-2d8xge7dgkzx.html",
      "time_published": "20251119T120925",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed (Nasdaq: PBM) has secured a sustainable, high-potency supply of iboga bark through its partner PsyLabs, with an initial 50 kg shipment processed into GMP-compliant ibogaine HCl and Total Alkaloid Extracts. This achievement is crucial for the clinical development of pharmaceutical-grade ibogaine for substance use disorders and research markets. The collaboration emphasizes ethical sourcing, sustainability, and benefit-sharing with source communities to establish a vertically integrated supply chain.",
      "banner_image": "https://ml.globenewswire.com/media/ZmQ5NThjNTUtMDJlNi00MTFhLTg0M2ItODkwMzhhZDBlYTFiLTEyOTc0NjctMjAyNS0xMS0yMC1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949169"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.722557"
        }
      ],
      "overall_sentiment_score": -0.380193,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.383974",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets",
      "url": "https://www.sahmcapital.com/news/content/psyence-biomed-reaches-major-breakthrough-in-pharmaceutical-grade-ibogaine-supply-for-worldwide-clinical-and-therapeutic-markets-2025-11-20",
      "time_published": "20251118T141004",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed, a biopharmaceutical company focusing on psychedelic-based therapeutics, announced a major breakthrough in securing a sustainable, ethically sourced supply of high-potency iboga bark through its partner, PsyLabs. This achievement ensures a GMP-compliant supply of ibogaine HCL and Total Alkaloid Extracts for clinical development and research into substance use disorders. The collaboration positions Psyence BioMed as a leader in the ibogaine sector, emphasizing ethical sourcing, sustainability, and fair benefit-sharing with indigenous communities.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.939621"
        },
        {
          "topic": "finance",
          "relevance_score": "0.607455"
        }
      ],
      "overall_sentiment_score": 0.490162,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453294",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs",
      "url": "https://www.globenewswire.com/news-release/2025/11/12/3186071/0/en/Psyence-BioMed-Establishes-Ibogaine-Operations-in-Africa-Through-Strategic-Investment-in-PsyLabs.html",
      "time_published": "20251117T043322",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed announced its strategic investment in PsyLabs, making it the only publicly listed psychedelics company with active ibogaine operations and manufacturing in Africa. This move ensures traceable, sustainable, and responsible access to ibogaine, which is native to Central and West Africa, while positioning Psyence BioMed advantageously in the rapidly growing psychedelics sector. The company's vertical integration from cultivation to purification, coupled with growing global interest and investment in ibogaine research (including a $50 million allocation in Texas), highlights its commitment to ethical sourcing and scientific advancement of nature-derived therapies.",
      "banner_image": "https://ml.globenewswire.com/media/ODZhY2JhZDgtZDRiZi00MTE4LWIxMWQtYmNjZmI4OWM2MGFhLTEyOTc0NjctMjAyNS0xMS0xMi1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.927043"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.611298"
        }
      ],
      "overall_sentiment_score": 0.389525,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.490690",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "ABBV",
          "relevance_score": "0.713809",
          "ticker_sentiment_score": "0.295776",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed (Nasdaq: PBM) invests $3,500,000 in PsyLabs for GMP-grade API supply",
      "url": "https://www.stocktitan.net/news/PBM/psyence-bio-med-strengthens-strategic-partnership-with-psy-labs-der14qp02c0z.html",
      "time_published": "20251108T043321",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed announced a $3,500,000 follow-on investment in PsyLabs, a producer of psychedelic active pharmaceutical ingredients (APIs). This investment, following an earlier $500,000 investment in April 2025, secures PsyLabs as a primary supplier of GMP-grade psilocybin and ibogaine for Psyence BioMed's clinical programs. The move aims to establish an ethical, sustainable supply chain from Southern Africa and strengthen Psyence BioMed's position in the emerging psychedelic therapeutics sector.",
      "banner_image": "https://ml.globenewswire.com/media/YWJiYjg0ZDYtMDllOC00ZWY3LTkwMmYtZTdmNzVjOWFlZGQxLTEyOTc0NjctMjAyNS0xMS0wMy1lbg==/tiny/Psyence-Biomedical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "finance",
          "relevance_score": "0.835526"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.747044"
        }
      ],
      "overall_sentiment_score": 0.419011,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.438246",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025",
      "url": "https://finance.yahoo.com/news/psyence-biomed-present-h-c-120000185.html",
      "time_published": "20250828T141005",
      "authors": [
        "NULL"
      ],
      "summary": "Psyence BioMed announced it will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Dr. Neil Maresky will outline the company's strategy and pipeline for global investors, highlighting its unique approach in psychedelic medicine. A webinar for investors and shareholders featuring the Scientific Advisory Board is also scheduled for September 16, 2025, to discuss clinical development and strategic initiatives.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/ZzRllEwmBJRmtO.L0Gf1ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.905409"
        },
        {
          "topic": "finance",
          "relevance_score": "0.730086"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.638688"
        }
      ],
      "overall_sentiment_score": 0.308794,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.328121",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "PBM Stock Price and Chart \u2014 NASDAQ:PBM",
      "url": "https://www.tradingview.com/symbols/NASDAQ-PBM/",
      "time_published": "20241231T235959",
      "authors": [],
      "summary": "This article provides a detailed overview of Psyence Biomedical Ltd. (NASDAQ: PBM) stock, including its current price, historical performance, key financial statistics, and company information. It covers market capitalization, revenue, employee data, and offers technical analysis insights along with frequently asked questions about the stock.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.943230"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.812471"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.929914"
        }
      ],
      "overall_sentiment_score": -0.622308,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.639082",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical Ltd. Closes $2 Million Private Placement Offering of Common Shares and Warrants",
      "url": "https://www.nasdaq.com/articles/psyence-biomedical-ltd-closes-2-million-private-placement-offering-common-shares-and",
      "time_published": "20241227T161000",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "Psyence Biomedical Ltd. has successfully closed a private placement, raising $2 million through the sale of common shares and warrants. The proceeds will be used for working capital and general corporate purposes, advancing the company's focus on developing psilocybin-based psychedelic medicines for mental health disorders, particularly in palliative care. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.802334"
        },
        {
          "topic": "finance",
          "relevance_score": "0.707058"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.649984"
        }
      ],
      "overall_sentiment_score": 0.27966,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "0.966049",
          "ticker_sentiment_score": "0.268606",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical Launches Patient Screening for Phase IIb Clinical Trial of Psilocybin in Palliative Care",
      "url": "https://www.nasdaq.com/articles/psyence-biomedical-launches-patient-screening-phase-iib-clinical-trial-psilocybin",
      "time_published": "20241217T084200",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "Psyence Biomedical Ltd. has initiated patient screening for its Phase IIb clinical trial evaluating nature-derived psilocybin with psychotherapy for Adjustment Disorder in palliative care patients. Two sites in Australia are active, with patient randomization expected to begin in January 2025. The company has partnered with Australian Clinical Trial Network (ACTioN) to enhance recruitment, anticipating topline results in the second half of 2025.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.318318,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.339707",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Psyence Biomedical faces Nasdaq delisting over market value By Investing.com",
      "url": "https://au.investing.com/news/company-news/psyence-biomedical-faces-nasdaq-delisting-over-market-value-93CH-3442480",
      "time_published": "20240914T063800",
      "authors": [
        "Investing.com"
      ],
      "summary": "Psyence Biomedical (NASDAQ: PBM) is facing delisting from Nasdaq due to its failure to meet minimum market value requirements. The company, which specializes in psilocybin-based therapeutics, plans to request a hearing to appeal the decision. Recent financial data reveals a market cap of $2.72 million USD and a significant drop in its 1-year price total return by 98.53%.",
      "banner_image": null,
      "source": "Investing.com Australia",
      "category_within_source": "General",
      "source_domain": "Investing.com Australia",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948596"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.830104"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.733272"
        },
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.627517"
        }
      ],
      "overall_sentiment_score": -0.609325,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.639189",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Psyence pays $500k to acquire fellow psilocybin biotech Clairvoyant and phase 2 AUD asset",
      "url": "https://www.fiercebiotech.com/biotech/pysence-pays-500k-acquire-fellow-psilocybin-biotech-clairvoyant-and-its-phase-2-aud-asset",
      "time_published": "20240906T092500",
      "authors": [
        "James Waldron"
      ],
      "summary": "Psyence Biomedical is acquiring Clairvoyant Therapeutics for $500,000 in shares, plus potential milestone payments and $1.8 million for liabilities. This acquisition brings Clairvoyant's phase 2 psilocybin candidate for alcohol use disorder (AUD) into Psyence's pipeline, complementing its existing cancer-related psilocybin program. The deal could expand Psyence's market and position it as a leader in psychedelic-based therapeutics for mental health.",
      "banner_image": null,
      "source": "Fierce Biotech",
      "category_within_source": "General",
      "source_domain": "Fierce Biotech",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.949942"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845746"
        }
      ],
      "overall_sentiment_score": 0.247186,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.436401",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "LLY",
          "relevance_score": "0.623528",
          "ticker_sentiment_score": "0.127326",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.629877",
          "ticker_sentiment_score": "0.103855",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Psyence Biomed Announces Acquisition of Psilocybin Drug Developer Clairvoyant Therapeutics",
      "url": "https://microdose.buzz/news/psyence-biomed-acquisition-clairvoyant/",
      "time_published": "20240906T000000",
      "authors": [
        "Microdose NewsDesk"
      ],
      "summary": "Psyence Biomed (Nasdaq: PBM) announced a conditional binding term sheet to acquire Clairvoyant Therapeutics, a clinical-stage developer of psilocybin-based therapeutics. The acquisition aims to expand Psyence Biomed's pipeline into Alcohol Use Disorder (AUD) treatment with Clairvoyant's synthetic psilocybin candidate, currently in a Phase IIb clinical trial with topline data expected in early 2025. This strategic move complements Psyence Biomed's existing nature-derived psilocybin development and positions them for lead roles in psychedelic-based treatments.",
      "banner_image": null,
      "source": "microdose.buzz",
      "category_within_source": "General",
      "source_domain": "microdose.buzz",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "0.901247"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.913720"
        }
      ],
      "overall_sentiment_score": 0.496409,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.498198",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial",
      "url": "https://www.marketscreener.com/quote/stock/PSYENCE-GROUP-INC-118263377/news/Psyence-Group-s-NASDAQ-Listed-Associate-Psyence-Biomedical-Announces-Export-of-Nature-Derived-Psil-47482705/",
      "time_published": "20240726T093000",
      "authors": [],
      "summary": "Psyence Group's NASDAQ-listed associate, Psyence Biomedical (PBM), has announced the export of nature-derived psilocybin to Australia, a crucial step for its upcoming Phase IIb clinical trial. PBM is preparing to initiate patient enrollment for the study, which will evaluate two therapeutic doses of psilocybin against an active low-dose comparator in 84 patients. Additionally, the companies have mutually agreed to terminate a commercial licensing agreement with Filament Health Corp., with PBM actively seeking alternative suppliers for its psilocybin needs.",
      "banner_image": null,
      "source": "MarketScreener",
      "category_within_source": "General",
      "source_domain": "MarketScreener",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929187"
        }
      ],
      "overall_sentiment_score": 0.423237,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "PBM",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.394606",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}